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Abstract 
Polymeric nanoparticles have revealed very effective in transmucosal delivery of 
proteins. Polysaccharides are among the most used materials for the production of these 
carriers, owing to their structural flexibility and propensity to evidence biocompatibility 
and biodegradability. In parallel, there is a preference for the use of mild methods for 
their production, in order to prevent protein degradation, ensure lower costs and easier 
procedures that enable scaling up. 
In this work we propose the production of pullulan-based nanoparticles by a mild 
method of polyelectrolyte complexation. As pullulan is a neutral polysaccharide, 
sulfated and aminated derivatives of the polymer were synthesized to provide pullulan 
with a charge. These derivatives were then complexed with chitosan and carrageenan, 
respectively, to produce the nanocarriers. Positively charged nanoparticles of 180-270 
nm were obtained, evidencing ability to associate bovine serum albumin, which was 
selected as model protein. In PBS pH 7.4, pullulan-based nanoparticles were found to 
have a burst release of 30% of the protein, which maintained up to 24h. Nanoparticle 
size and zeta potential were preserved upon freeze-drying in the presence of appropriate 
cryoprotectants. A factorial design was approached to assess the cytotoxicity of raw 
materials and nanoparticles by the metabolic test MTT. Nanoparticles demonstrated to 
not cause overt toxicity in a respiratory cell model (Calu-3). Pullulan has, thus, 
demonstrated to hold potential for the production of nanoparticles with an application in 
protein delivery.  
 
 
Keywords: carrageenan, chitosan, drug delivery, nanoparticles, protein delivery, 
pullulan 
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1. Introduction 
Finding adequate strategies to deliver proteins has become an urgent scientific 
challenge, and transmucosal administration is now the first-line option for their 
systemic delivery. Nanoparticles have been proposed as suitable protein carriers, 
overcoming many of the limitations posed by the physicochemical characteristics of 
these macromolecules, which are very susceptible to degradation and undergo difficult 
absorption due to their size and, usually, hydrophilicity (Antosova et al., 2009; Liu et 
al., 2008). Nanoparticles potentiate the improvement of drug pharmacokinetic profile, 
not only by providing their stabilisation but, in some cases, also permitting controlled 
release and enhancing drug absorption (Grenha, 2012; Hartig et al., 2007). Morevover, 
the high surface-to-volume ratio displayed by nanoparticles increases drug loading 
capacity (de la Fuente et al., 2008a). Previous studies have demonstrated that 
nanoparticle contact with epithelial surfaces is maximised when they display a size 
within 50 and 500 nm (Desai et al., 1996; Jani et al., 1990) and a strongly positive zeta 
potential (Bogataj et al., 2003; Carvalho et al., 2010). 
Polymers have been referred as the best class of materials to produce nanoparticles and 
polysaccharides are among the most used (Karewicz et al., 2012; Liu et al., 2008), 
because their natural origin offers better potential for complying with the requisites of 
biocompatibility and biodegradability, which are mandatory in the design of drug 
delivery systems (Beneke et al., 2009; Liu et al., 2008; Malafaya et al., 2007). 
Moreover, polysaccharides also exhibit great structural flexibility, forming either linear 
or branched structures and easily permitting chemical modifications (Karewicz et al., 
2012; Malafaya et al., 2007). In recent years, the most frequently explored 
polysaccharide for the design of nanodelivery systems was chitosan, a cationic polymer 
composed of repeating β-(1,4)-linked N-acetylglucosamine and D-glucosamine units, 
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which is obtained by chitin deacetylation and assumes different molecular weights and 
deacetylation degrees (Chiellini et al., 2008; Hassani et al., 2012; Mizrahy and Peer, 
2012). Apart from the reported biocompatibility and biodegradability (Dornish et al., 
1997; Grenha et al., 2010a; Hirano et al., 1988), the most outstanding properties of 
chitosan rely on its mucoadhesive character (Lehr et al., 1992) and demonstrated ability 
to potentiate transmucosal absorption both as molecule (Artursson et al., 1994; 
Borchard et al., 1996; Portero et al., 2002) and in the form of nanoparticle (Al-Qadi et 
al., 2012; De Campos et al., 2001; Fernández-Urrusuno et al., 1999a; Prego et al., 
2005a; Yamamoto et al., 2005).  
Other polysaccharides integrating the list of ―most used‖ in similar applications are 
alginate, dextran and hyaluronic acid, but the universe of polysaccharides is much wider 
and includes many other polymers that might also exhibit potential. Carrageenan is one 
of the examples, having a limited number of reported applications in drug delivery. It is 
extracted from red seaweed and is composed of galactose and 3,6-anhydrogalactose 
units, linked by alternating α-(1,3) and β-(1,4) glycosidic bonds (Malafaya et al., 2007; 
Rinaudo, 2008). Our group has previously reported its use as nanoparticle forming 
material for drug delivery applications (Grenha et al., 2010b; Rodrigues et al., 2012b). 
Another of those molecules is pullulan, a neutral polymer consisting of α-(1,6)-linked 
maltotriose residues, which in turn are composed of three glucose molecules connected 
to each other by an α-(1,4) glycosidic bond (Chiellini et al., 2008; Mizrahy and Peer, 
2012; Namazi et al., 2011). Pullulan is produced from starch by the fungus 
Aureobasidium pullulans and evidences water solubility (Leathers, 2003; Rekha and 
Chandra, 2007). Interestingly, it is believed to have a role on the adhesion of the 
referred fungus to biological surfaces, such as leafs (Pouliot et al., 2005), which might 
unveil bioadhesive properties that are relevant for mucosal/transmucosal applications. 
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Moreover, it is expected to be biodegradable, being exposed to the hydrolysis of 
glycoside bonds and the subsequent metabolism of glucose (Teramoto and Shibata, 
2006). Pullulan has been described for the production of drug and gene nanocarriers 
(Cheng et al., 2011; Gupta and Gupta, 2004b; Jeong et al., 1999; Nochi et al., 2010; 
Rekha and Chandra, 2007; Shimizu et al., 2008), mainly using hydrophobic derivatives. 
Pullulan-based nanoparticles were reported to adhere to the nasal epithelium in a study 
regarding nasal vaccination, demonstrating to exhibit a very important property 
regarding mucosal administration (Nochi et al., 2010), reinforcing the potential for 
bioadhesion, 
Many polysaccharides might assemble into nanoparticles by a simple and mild method 
of polyelectrolyte complexation, simply taking benefit from the electrostatic interaction 
potentiated by opposite charges (Grenha, 2012). The use of organic solvents and other 
potentially aggressive preparation conditions is thus avoided, not compromising the 
stability of encapsulated molecules during nanoparticle preparation (Agnihotri et al., 
2004; Janes et al., 2001) and, possibly, contributing to increased biocompatibility. 
Using neutral polysaccharides like pullulan demands synthesizing charged chemical 
derivatives that enable using the referred methodology to produce nanoparticles. 
In this study, we aimed at exploring the potential of pullulan to produce protein 
nanocarriers adequate for nasal and lung transmucosal delivery (e.g.), using a mild 
polyelectrolyte complexation technique. Both positively and negatively charged 
pullulan derivatives were synthesized and complexed with carrageenan and chitosan, 
respectively, to produce the nanocarriers. To succeed on the approach, the nanoparticles 
should efficiently associate proteins such as the model bovine serum albumin (BSA), 
evidence adequate size (up to 500 nm) and positive zeta potential, and be devoid of cell 
toxicity. 
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2. Experimental 
2.1. Chemicals 
Chitosan (CS, low molecular weight, deacetylation degree = 75-85%), glacial acetic 
acid, phosphotungstic acid, glycerol, BSA, phosphate buffered saline (PBS) tablets pH 
7.4, glucose, sucrose, lactose, trehalose, thiazolyl blue tetrazolium bromide (MTT), 
dimethyl sulfoxide (DMSO), dialysis tubing benzoylated 32 mm (1.27 in), Dulbecco’s 
Modified Eagle’s Medium (DMEM), non-essential amino acids (100%), L-glutamine 
200 mM, penicillin-streptomycin solution, trypsin-EDTA solution and  trypan blue 
solution (0.4%) were supplied by Sigma Chemicals (Germany). Pullulan was kindly 
provided by Hayashibara (Japan). ƙ -Carrageenan (CRG) and potassium bromide (KBr) 
were obtained from FMC Biopolymer (Norway) and Riedel-del-Haën (Germany), 
respectively. Foetal bovine serum (FBS) was supplied by Invitrogen (USA). 
Acetonitrile (HPLC grade) was purchased from JT Baker (Netherlands) and 
trifluoroacetic acid (TFA) from Alfa Aesar (Germany). Ultrapure water (Mili-Q Plus, 
Milipore Iberica,Spain) was used throughout. All other reagents were chemical grade. 
Prior to use, acetonitrile and 0.1% TFA aqueous solution prepared with ultrapure water 
were filtered with a 0.2 μm filter.  
 
2.2. Cell line 
The Calu-3 cell line was obtained from the American Type Culture Collection 
(Rockville, USA) and cells were used between passages 37-50. Cells were grown using 
75 cm
2
 flasks in a humidified 5% CO2/95% atmospheric air incubator at 37 ºC. The 
used cell culture medium was 500 ml DMEM, supplemented with 10% foetal bovine 
serum (FBS), 1% non-essential amino acid solution, 1% L-glutamine and 1% 
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penicillin–streptomycin. Medium was exchanged every 2-3 days and cells were 
subcultured weekly. 
 
2.3. Synthesis of pullulan derivatives 
Pullulan was chemically modified in order to obtain two derivatives with opposite 
charge. The negatively charged derivative (sulfated pullulan, SP) was obtained through 
sulfation of pullulan, while the positively charged derivative (aminated derivative, AP) 
was synthesised by amination of the original polymer. Both synthesis were performed 
according to previously described methodologies (Simkovic et al., 2009; Yuan et al., 
2005) and are specifically described elsewhere (Dionísio et al., 2011). For the 
preparation of the aminated pullulan, the alkylating agent (glycidyltrimethylammonium 
chloride; 9 eq) was added to a solution of the polymer in aqueous potassium hydroxide 
(0.1 g/ml of the polymer and 9 eq of the base) and the resulting mixture heated at 60 ºC 
for 24h. The solution was then neutralised by the addition of HCl (2M). In the 
preparation of the sulfate derivative, the sulfation agent (SO3•DMF complex) was first 
obtained by dropping 20 ml of HClSO3 into 100 ml of cooled DMF. Pullulan was 
dispersed in DMF at approximately 0.025 g/mL by heating at 60 ºC for 30 min and then 
the SO3•DMF complex (9 eq) was added and the mixture allowed to react at the above 
temperature for 4 h. The mixture was then allowed to cool down and was neutralized 
with 30% NaOH solution. Both modified polymers were purified by dialysis, recovered 
by precipitation from ethanol, separated from the supernatant by centrifugation and 
dried under vacuum. 
 
2.4. Preparation of pullulan-based nanoparticles 
Different formulations of nanoparticles were prepared by polyelectrolyte complexation, 
combining SP with CS and AP with CRG, thus obtaining SP/CS and CRG/AP 
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nanoparticles. To do so, CS was dissolved in 1% (w/w) acetic acid to obtain a solution 
of 1.0 mg/ml (pH 3.2), SP and AP were dissolved in purified water to obtain stock 
solutions of 1.0 mg/ml (pH 4.5 and 5.7, respectively) and CRG was dissolved in water, 
resulting in a stock solution of 2.5 mg/ml (pH 6.7). 
All nanoparticle formulations were produced by dropping 1 ml of the solution 
containing the polymer present in the lower amount (negatively charged polymer) over 
1 ml of the polymer present in higher amount (positively charged polymer), under mild 
magnetic stirring (approximately 10 min), at room temperature. CS and AP assumed a 
fixed concentration of 1 mg/ml in the formulations SP/CS and CRG/AP, respectively, 
and the other stock solutions were appropriately diluted to obtain nanoparticles of 
SP/CS and CRG/AP mass ratios of 1/2, 1/3 and 1/4 (w/w). The pH of nanoparticle 
suspensions was 3.3 and 5.9 for SP/CS and CRG/AP, respectively. Nanoparticles were 
then isolated by centrifugation at 16,000 × g on a 10 µl glycerol layer for 30 min at 15 
ºC (Eppendorf 5804R, Eppendorf, Germany). The supernatants were discarded and 
nanoparticles were ressuspended in 200 µl of purified water. 
BSA was chosen as a model protein and was incorporated in the formulations (SP/CS = 
1/2 and CRG/AP = 1/2) in a theoretical content of 30% (w/w) respective to the polymer 
present at the higher concentration (CS or AP). To prepare protein-loaded nanoparticles, 
BSA was dissolved in water and mixed with the solution corresponding to the polymer 
present in the lower amount prior to dropping over the other polymer for the 
polyelectrolyte complexation to take place (the pH of SP/BSA mixture is 5.1 and that of 
CRG/BSA mixture is 6.5). The final pH of BSA-loaded nanoparticles was the same 
observed for the unloaded nanoparticles. 
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2.5. Characterisation of nanoparticles 
The morphological examination of nanoparticles was conducted by transmission 
electron microscopy (TEM) (JEM- 1011, JEOL, Japan). Samples were stained with 2% 
(w/v) phosphotungstic acid and placed on copper grids with carbon films (Ted Pella, 
USA) for TEM observation. Measurements of nanoparticle size and zeta potential were 
performed on freshly prepared samples by photon correlation spectroscopy and laser 
Doppler anemometry, respectively, using a Zetasizer Nano ZS (Malvern Instruments, 
Malvern, UK). For the analysis of particle size and determination of the electrophoretic 
mobility, each sample was diluted to the appropriate concentration with ultrapure water 
and placed in the electrophoretic cell (n  3). 
 
2.6. Determination of nanoparticle production yield 
The yield of nanoparticle production was calculated by gravimetry. Fixed volumes of 
nanoparticle suspensions were centrifuged (16,000 × g, 30 min, 15 ºC), and sediments 
were freeze-dried using a Labconco freeze dryer (Labconco, USA) (n = 6). 
The production yield (PY) was calculated as follows:  
PY = (Nanoparticle sediment weight / Total solids weight) x 100            (Eq. 1) 
where nanoparticle sediment weight is the weight after freeze-drying and total solids 
weight is the total amount of solids added for nanoparticle formation. 
 
2.7. Nanoparticle analysis by Fourier transform infrared (FTIR) spectroscopy  
The presence of the different components of the nanoparticulate systems was verified by 
FTIR. Infrared spectra of the specimen powders, namely CS, CRG, AP and SP, as well 
as of the two formulations of nanoparticles (SP/CS = 1/2 and CRG/AP = 1/2), were 
recorded using a FTIR spectrophotometer (Tensor 27, Bruker, Germany). BSA-loaded 
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nanoparticles were assessed in the same conditions, and BSA was also analysed as 
control. 
Nanoparticles were freeze-dried prior to the assay and all the samples were gently 
triturated with KBr and compressed into discs for the analysis.  
For each spectrum a 32-scan interferogram was collected in transmittance mode with a 
4 cm
-1
 resolution in the 4000–400 cm-1 region at room temperature. 
 
2.8. Determination of protein loading capacity of nanoparticles 
BSA association efficiency was determined upon separation of nanoparticles from the 
aqueous preparation medium containing the non-associated protein by centrifugation 
(16,000 × g, 30 min, 15 ºC). The amount of free BSA was determined in the supernatant 
by HPLC (Agilent 1100 series, Germany). The chromatographic conditions used to 
quantify the protein were: mobile phase consisted of acetonitrile and 0.1% TFA aqueous 
solution initially set in the ratio 30:70 (v/v), which was linearly changed to 40:60 (v/v) 
over 5 min. From 5 to 10 min the ratio 40:60 (v/v) was kept constant. Eluent was 
pumped at a flow rate of 1 ml/min, the injection volume was 20 µl and detection 
wavelength was 280 nm. A calibration curve of the protein was made in PBS (pH 7.4). 
All experiments occurred at room temperature and the total area of the peak was used to 
quantify BSA (n = 3).  
The protein association efficiency (AE) and the loading capacity (LC) of nanoparticles 
were calculated as follows: 
AE (%) = [(Total BSA amount – Free BSA amount) / Total BSA amount] x 100    (Eq. 2) 
LC (%) = [(Total BSA amount – Free BSA amount) / Nanoparticle weight] x 100  (Eq. 3) 
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2.9. In vitro release of BSA from nanoparticles 
The release of BSA was determined by incubating 1 ml of nanoparticles of each 
formulation (SP/CS = 1/2 and CRG/AP = 1/2) in 5 ml PBS pH 7.4, under horizontal 
shaking at 37 °C. At appropriate time intervals (1, 2, 3, 4, 6, 8 and 24h) samples of 100 
µl were collected to quantify the amount of protein released by HPLC (Agilent

 1100 
series, Germany). Each time a sample was removed, the corresponding volume was 
replaced with the same amount of PBS (n = 3). 
 
2.10. Study of nanoparticle stability and freeze-drying 
Aliquots of nanoparticle formulations (SP/CS = 1/2 and CRG/AP = 1/2) were kept at 4 
◦C to evaluate nanoparticle stability upon storage. Size and zeta potential were 
monitored as a function of time for approximately 30 days, using the techniques 
described above (n = 3). 
With the aim of developing a pharmaceutically-acceptable dry form of the nanoparticle 
suspensions, the same formulations were submitted to a freeze-drying study. 
Nanoparticles were concentrated by centrifugation and their concentration was set at 2 
mg/ml. Nanoparticle suspensions (1 ml) were freeze-dried in the presence of four 
carbohydrates (sucrose, glucose, lactose and trehalose), which were used separately as 
cryoprotectants and tested at different concentrations (2.5, 5 and 10%, w/v). Samples 
were freeze-dried under the following conditions: pressure of 50-100 Torr, 24h of 
primary drying starting at -35 ºC and gradually increasing until -10 ºC, 24h at 0 ºC and a 
final step of secondary drying (12 – 24h) at 15 ºC (Labconco Corp., USA). After freeze-
drying, the nanoparticles were resuspended by adding the volume of water 
corresponding to the initial volume (1 ml), and their size and zeta potential were 
determined as indicated above. 
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2.11. In vitro cytotoxicity study of pullulan-based nanoparticles  
The in vitro cytotoxicity of pullulan-based nanoparticles, as well as that of the raw 
materials involved in nanoparticle production, was assessed by the metabolic assay 
thiazolyl blue tetrazolium bromide (MTT) test. The original unmodified polymer of 
pullulan was also assessed. Cells were seeded at a density of 2.5  104 cells/well in 96 
well plates, suspended in 100 µl of cell culture medium. After 24h at 37 ºC in 5% CO2 
atmosphere, the medium was replaced by fresh medium containing the test samples with 
polymers/nanoparticles or controls. Cells incubated with either 2% (w/v) SDS solution 
or culture medium were used, respectively, as positive and negative control of cell 
death. All formulations and controls were prepared in pre-warmed cell culture medium 
without FBS immediately before application to the cells. Samples were tested for 3h 
and 24h at different concentrations (0.1, 0.5 and 1.0 mg/ml). After incubation with the 
test solutions, the medium containing the particles/polymers was removed and 30 µl of 
MTT solution (0.5 mg/ml in PBS, pH 7.4) added on each well. After 2h, the medium 
was removed and the formazan crystals dissolved in 50 µl of DMSO. The absorbance of 
each well was measured by spectrophotometry using a plate reader (Teacan-Infinite 
M200, Switzerland) at 540 nm and corrected for background absorbance using a 
wavelength of 650 nm.  
Cell viability was calculated as follows: 
Cell viability (%) = (A-S)/(CM-S)       (Eq. 4) 
where A is the absorbance obtained for each of the concentrations of the test substance, 
S is the absorbance obtained for 2% SDS and CM is the absorbance obtained for 
untreated cells (incubated with cell culture medium). The latter reading was assumed to 
correspond to 100% cell viability. The assay was performed on three occasions with six 
replicates at each concentration of test substance in each instance. 
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2.12. Statistical analysis 
For the generality of results, the t-test and the one-way analysis of variance (ANOVA) 
with the pairwise multiple comparison procedures (Student-Newman-Kleus Method) 
were performed to compare two or multiple groups, respectively. These analyses were 
run using the SigmaStat statistical program (Version 3.5, SyStat, USA).  
The cytotoxicity assay was performed according to a factorial design (FD), used to 
investigate the effect of time (X1), concentration (X2) and polymers/nanoparticles (X3) 
on cell viability (Y). A three-way ANOVA with three independent variables was 
performed and the levels of two variables were the following: 3h, 24h (X1) and 0.1, 0.5 
and 1 (X2). The third variable (X3) has different attributes: 1) when polymers are 
considered, the levels of X3 are CS, CRG, pullulan, AP and SP; in the case of 
nanoparticles, the levels are CRG/AP and SP/CS. For either polymers or nanoparticles, 
the objective is to investigate the influence of the three factors (X1, X2 and X3) on the 
response factor (Y). Further analyses with Post hoc tests were used to determine which 
groups differ. FD was performed with SPSS (version 21.0 for windows) and the effect 
plots were obtained with package gplots from R 2.15.3 software (Meyres et al., 2012; R 
Core Team, 2013). 
All the statistical analyses were performed at a level of significance of α = 5%.  
 
3. Results and Discussion 
3.1. Preparation and characterisation of nanoparticles 
Several formulations of pullulan-based nanoparticles were produced by a mild 
procedure of polyelectrolyte complexation that involves an electrostatic interaction 
between oppositely charged polymers. This is a very simple procedure, which most 
important advantages are the complete hydrophilic environment and the mild 
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preparation conditions, thus avoiding the use of organic solvents or high shear forces 
(Grenha, 2012; Prego et al., 2005b). From its characteristics, pullulan holds potential for 
the preparation of nanocarriers. However, it is a neutral polymer and, therefore, cannot 
be used directly to obtain nanoparticles by this methodology. To overcome this 
limitation, a positively charged amine derivative (137 kDa) and a negatively charged 
sulfated derivative (10 kDa) of pullulan were synthesised (Dionísio et al., 2011). Based 
on the estimations performed from elemental analysis data, the sulfation reaction 
resulted in approximately 4 sulfate groups per maltotriose unit (SP), while a degree of 
substitution of approximately 3 amino groups per repeating unit was found for AP. The 
former was assumed to be in the sodium salt form, to which corresponds a mass of 904 
g/mol and, the latter, to be in the form of chloride salt, with a mass of 885 g/mol 
(unpublished results). For CS, a mean value of 0.8 positive charges per monomer, and 
an average monomeric molecular weight of 169 g/mol were used. Carrageenan was 
assumed to be in the sodium salt form, to which corresponds a mass of 408 g/mol and a 
negative charge per disaccharide monomer unit (Rodrigues et al., 2012b). 
The chemical structures of pullulan derivatives, as well as those of the other polymers 
involved in the production of nanoparticles are depicted in Figure 1A. 
Unloaded SP/CS and CRG/AP nanoparticles of mass ratios 1/2, 1/3 and 1/4 were 
prepared, the former displaying sizes around 250 nm and the latter around 180 nm, and 
all showing high positive zeta potential. For both polymeric compositions, minimal 
changes on size and zeta potential were observed due to mass ratio modification (data 
not shown). For both formulations SP/CS and CRG/AP, the mass ratio of 1/2 displayed 
higher production yield, which is easily justified by the proper mechanism of 
nanoparticle formation due to electrostatic interaction. CS and AP were used at a fixed 
concentration of 1 mg/ml in each formulation and the second polymer was added in 
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variable concentrations (the amount decreasing from 1/2 to 1/4) to obtain the different 
mass ratios. Therefore, as the formulations with mass ratio 1/2 are those integrating the 
higher amount of negative polymer, a higher degree of interaction between negatively 
and positively charged groups is potentiated, leading to the formation of a higher 
number of nanoparticles (Fernández-Urrusuno et al., 1999b; Grenha et al., 2005; 
Rodrigues et al., 2012b). In fact, in SP/CS formulations, positive to negative (+/-) 
charge ratios vary from 2 to 4, and in CRG/AP formulations, from 3 to 6, as the amount 
of negatively charged polymer decreases. Therefore, mass ratios of 1/2 approach the 
most the stoichiometric amount of charges. 
Taking this into account, the formulations SP/CS and CRG/AP of mass ratio 1/2 were 
selected to perform further studies. As can be observed in Figure 2, pullulan-based 
nanoparticles evidence similar structure and morphology, corresponding to spherical 
and compact nanoparticles. This morphology corresponds to that widely reported for 
many formulations of polysaccharide-based nanoparticles (Calvo et al., 1997b; 
Goycoolea et al., 2009; Oyarzun-Ampuero et al., 2009; Sarmento et al., 2006; Teijeiro-
Osorio et al., 2009; Zorzi et al., 2011). 
The physicochemical properties of these nanoparticles are displayed in Table 1. SP/CS 
nanoparticles display a size of 260 nm and a strong positive zeta potential of +50 mV. 
CRG/AP nanoparticles have a lower size of approximately 185 nm (P < 0.05) and a 
similar zeta potential of +56 mV. The positive zeta potential results from the higher 
amount of the positively charged polymer in both cases. The polydispersion index is in 
all cases between 0.2 and 0.4 and production yields are similar for both formulations 
(around 55 – 60%).  
The difference registered for the nanoparticle size might result from different intensity 
of electrostatic interactions due to the use of polymers with different charge densities. 
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Lower charge ratios thus lead to the formation of larger nanoparticles, as happens for 
the SP/CS formulation, because there is a higher amount of negative charges to 
neutralise the positive groups, reducing electrostatic repulsion. Actually, although not to 
a significant level, the zeta potential of SP/CS nanoparticles is lower than that of 
AP/CRG nanoparticles, possibly reflecting the higher amount of negative charges 
present in the former formulation. This effect of size decrease with the increase of +/- 
charge ratio was previously reported in another work from our group, involving the 
preparation of chitosan/carrageenan nanoparticles (Rodrigues et al., 2012b). 
The presence of the different components on the nanoparticulate systems was assessed 
by FTIR. The obtained spectra are displayed in Figure 1B-C. The presence of SP in 
SP/CS nanoparticles is apparent in the respective spectrum by a S=O asymmetric 
stretching band at 1254 cm
-1
; although the CS amide bands are partially masked by the 
band of adsorbed water bending at approximately 1640 cm
−1
 (Wilson et al., 2000), its 
presence is denoted by the new band at 1541 cm
−1
 due to absorption of the protonated 
amino groups. Since the quaternary ammonium groups do not display characteristic IR 
absorption bands (Nakanishi et al., 1957), evidence for its presence in the AP/CRG 
nanoparticles comes from the bands at 1477 and 926 cm
-1
 (C-H scissoring in methyl 
groups of the ammonium and ether C-O asymmetric stretching, respectively) (Xu et al., 
2003); CRG presence is denoted by the sulfate band at 1261 cm
-1
. 
BSA was selected as model to test the ability of pullulan-based nanoparticles to 
associate proteins. The FTIR spectra of BSA-loaded nanoparticles evidence the 
effective association of protein to the nanoparticle structure. The spectra of loaded 
particles match those of the blank counterparts, evidencing incorporation of the two 
polymers in both formulations. In the case of SP/CS nanoparticles, the presence of the 
protein enhanced the intensity of the 1645 and 1541 cm
-1
 bands, due to superposition 
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with the amide I and amide II bands, respectively; the former was also shifted to a 
higher wavenumber. Also, the band at 1258 cm
-1
 is stronger in the loaded particles, due 
to superposition of the 1254 cm
-1
 band of sulphate and the amide III band, at 1247 cm
-1
.  
In the CRG/AP loaded particles, the presence of the protein is denoted by an intensity 
enhancement and shift to a higher wavenumber of the 1647 cm
-1
 band, the appearance 
of a new band at 1558 cm
-1
, and the broadening of the band at 1256 cm
-1
, for the 
aforementioned reasons. 
It is widely accepted that the interactions between proteins and polyelectrolytes are 
predominantly of electrostatic nature (Cooper et al., 2005). In fact, BSA presents both 
basic and acidic groups on its surface, in a fairly uniform distribution, providing the 
protein with an amphiphilic character. Due to that surface charge anisotropy, BSA 
presents positive and negative charge domains (―patches‖), the latter more dispersed. 
Such characteristics allow BSA to bind polyanions at pH > pI, where the protein 
presents a global negative charge, forming soluble complexes. This binding ―on the 
wrong side‖ of the pI was ascribed to an interaction of the polyanion with the positive 
domain of the protein, thus resulting in a combination of short-range attractive 
interactions coupled with longer-range repulsive interactions. Lowering the pH below pI 
leads to coacervation, due to charge neutralization of the polyanion by the globally 
positive protein (Seyrek et al., 2003). On the contrary, binding of BSA to polycations 
―on the wrong side‖ of the pI is not favored because its negative domains are 
fragmented, thus being ineffective at binding polycations, with the long-range repulsion 
prevailing over the short-range attraction. Only at pH above pI, where wider negative 
domains form, soluble complexes are observed, with coacervation occurring at even 
higher pH values (Chen et al., 2011). 
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As referred in section 2.4, BSA is mixed with either SP or CRG (the negatively charged 
polymers) prior to the addition to CS or AP solutions, respectively. The first mixture 
has, in both cases, a pH above BSA isoelectric point (4.7) and, therefore, BSA presents 
a negative charge. Under such circumstances, the formation of soluble complexes, with 
a global negative charge, between the protein and the polysaccharides is expected, thus 
potentiating the electrostatic interaction with the positively charged polymers and 
protein encapsulation. 
In this study, the physicochemical characteristics of nanoparticles generally remained 
unaltered after protein association, with the exception of a slight increase in AP/CRG 
nanoparticles size from 185 to 244 nm (P < 0.05). Although the general little or absent 
effect on physicochemical properties (size and/or zeta potential) upon BSA association 
is somewhat unexpected, it has been registered in several studies on nanoparticles 
obtained by polyelectrolyte complexation (de la Fuente et al., 2008b; Grenha et al., 
2007; Liu et al., 2007; Vandana and Sahoo, 2009). BSA association with 
macromolecules has been reported not to be uniform as, to a certain extent, the pattern 
of association is governed by the 3D conformation that the protein adopts at specific pH 
and ionic strength. The protein has both positive and negatively charged functional 
groups, but it also has hydrophobic regions that tend to fold in a 3D structure in aqueous 
environment (Yampolskaya and Platikanov, 2006). In turn, polymeric molecules might 
adopt a spread conformation in solution because of electrostatic repulsion between 
charged groups along the molecular chain. The carboxyl groups on the surface of a large 
protein like BSA may bind to positively charged groups at certain sites of the spread 
polymeric chain of either CS or AP, but still maintaining a compact structure of the 
protein itself, so as to keep an inner hydrophobic core. Therefore, it is possible to 
assume that protein association does not neutralise significantly the positive surface 
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charge of chitosan or aminated pullulan molecules (Gan and Wang, 2007). Also, 
although there is the possibility of further protein adsorption on the surface of formed 
nanoparticles, this would occur by interaction of the negative domains of the former, 
with the positive charge of the latter, therefore partially or totally neutralizing the 
protein negative global charge (Chen et al., 2011). Moreover, in the case of SP/CS 
nanoparticles, the final solution pH is 3.3, well below BSA pI. In this manner, eventual 
protein adsorption on the particles surface is not expected to enormously affect their 
surface potential, as was observed. 
Production yield remained between 20 and 30%, even after association of the protein. 
BSA was associated with efficiencies of approximately 35-45% for CRG/AP and SP/CS 
nanoparticles, achieving loadings around 30%. Comparisons established at this level 
with other works are possibly not very useful, as they will concern nanoparticles 
produced with different materials and even different proteins. Nevertheless, regarding 
the loading capacity, nanoparticles presented in this study evidence similar ability as 
that of other formulations of polysaccharide-based nanoparticles (Chen et al., 2008; 
Fernández-Urrusuno et al., 1999a; Grenha et al., 2007; Oyarzun-Ampuero et al., 2009). 
 
3.2. In vitro release of BSA from nanoparticles 
Figure 3 shows the in vitro release of BSA in PBS pH 7.4, a medium that intends to 
resemble the environment of mucosal surfaces like the pulmonary (Walters, 2002), 
although in some cases it has also been used in the context of nasal delivery (Amidi et 
al., 2006; Amidi et al., 2007; Fernández-Urrusuno et al., 1999a). Results indicate that, 
for both formulations, the release of BSA from nanoparticles shows an initial burst, 
releasing approximately 30% of the encapsulated protein in 2h. However, at that time a 
steady state is achieved and no further release is observed up to 24h. This initial burst 
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release might correspond to the amount of protein that is located at the surface of the 
nanoparticles, which thus easily desorbs, an effect that has been reported in other 
studies (Amidi et al., 2006). Other works available in the literature describe quite 
similar release behaviour. N-trimethylchitosan nanoparticles designed for nasal delivery 
also released rapidly (3h) 30% of the associated protein in the same medium, although 
the assay was not prolonged beyond that (Amidi et al., 2006). In chitosan/ 
tripolyphosphate nanoparticles it has been seen that BSA releases very slowly, for 
several days (Calvo et al., 1997a, b; Gan and Wang, 2007). However, in one of the 
mentioned works, at 48h the amount of release is around 30%, although no 
measurement was taken before this time (Calvo et al., 1997a), while in the other a 
release of approximately 30% was obtained in 24h (Gan and Wang, 2007). 
The relevance of this release profile is intimately dependent on the contextualisation 
with an administration route. If the approach of transmucosal lung delivery is 
considered, for instance, as exemplified above to justify the used release medium (pH 
7.4), it is generally accepted that particles remain in the lung for up to 24h, although 
those deposited in the alveolar zone might expect prolonged retention time because of 
the absence of mucociliary clearance (Hofmann and Asgharian, 2003; Möller et al., 
2006). In turn, if nasal administration is focused, for instance, the frequent turnover of 
nasal mucus will strongly decrease the retention time (Illum, 2002; Lansley and Martin, 
2001) and, even if mucoadhesive formulations are applied, shorter contact time is 
expected as compared with lung delivery. Nevertheless, if nasal delivery is focused, a 
pH that resembles more closely the environment of the nasal cavity (5.5 – 6.5) (Lansley 
and Martin, 2001) should be used for the release studies. 
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3.3. Nanoparticle stability in storage and upon freeze-drying 
One of the problems of colloidal drug carriers is their low stability and tendency to 
aggregate, which is known to be affected by many factors, with both physical 
(aggregation/particle fusion) and chemical instability (hydrolysis of polymer and 
chemical reactivity) appearing along time when nanocarriers are formulated as aqueous 
suspensions (Abdelwahed et al., 2006; Chacon et al., 1999; Kumar et al., 2012). The 
natural tendency for aggregation upon storage is actually one of the important 
limitations of nanoparticle application (Sameti et al., 2003; Wu et al., 2011). This 
tendency is attributed to the fact that, when two particles come into contact, the 
attractive potential is much greater than the kinetic energy that could induce their 
separation (Ikeda and Zhong, 2012). In this regard, the use of charged nanoparticles, as 
those described in this work, might prevent aggregation and has been proposed as 
strategy to increase nanoparticle stability. 
In order to study nanoparticle behaviour in storage, the size and zeta potential of SP/CS 
and CRG/AP nanoparticles were monitored along time. It was observed that, for up to 
approximately 1 month, both formulations maintain reasonably the initial 
physicochemical characteristics when stored at 4 °C (data not shown). There is a 
significant (P < 0.05), although slight, decrease in the zeta potential of CRG/AP 
nanoparticles at the beginning of the assay from +65 mV to +56 mV, but this did not 
induce any effect on nanoparticle size, as the zeta potential remains sufficiently high to 
induce repulsion of nanoparticles. Chitosan-based nanoparticles have been reported to 
exhibit physicochemical stability in similar time intervals (Hafner et al., 2009; Morris et 
al., 2011; Rodrigues et al., 2012b). No similar studies are reported for pullulan-based 
nanoparticles, thus not allowing a direct comparison. 
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Although pullulan-based nanoparticles demonstrated to remain stable at 4 ºC for at least 
one month, it was decided to develop lyophilized formulations that provide stability for 
longer periods of time. The optimal conditions for freeze-drying were studied, testing 
glucose, sucrose, trehalose and lactose as cryoprotectants. Formulations elaborated with 
both pullulan derivatives evidenced a general maintenance of zeta potential values (data 
not shown), as the ratio ―after freeze-drying/ before freeze-drying‖ varied between 1 
and 1.2. 
Figure 4 displays the variation of nanoparticle size when comparing that obtained after 
reconstitution of freeze-dried material (Df) with the initially determined (Di) before the 
freeze-drying process. The direct freeze-drying of nanoparticles (without 
cryoprotectants) did not preserve their properties (data not shown), leading to strong 
aggregation. This is justified by the high concentration of particles occurring during the 
freezing step and to the mechanical stress induced by ice crystallisation (Abdelwahed et 
al., 2006; Vauthier and Bouchemal, 2009). The two formulations of nanoparticles 
behaved differently in the presence of the tested cryoprotectants. CRG/AP nanoparticles 
(Figure 4A) were more difficult to stabilise than SP/CS nanoparticles (Figure 4B). In 
the former, glucose at a concentration of 5% or higher provided the best conditions for 
nanoparticle stabilisation during the freeze-drying process (P < 0.05), although a slight 
increase in the nanoparticle size was still observed (from 204 nm to 249 nm). Sucrose 
and trehalose had only a small cryoprotectant effect, as nanoparticle size was increased 
considerably (p < 0.05) after freeze-drying, doubling in several cases. Finally, lactose (a 
typical excipient used in lung delivery) revealed absolutely inefficient as cryoprotectant 
agent, permitting strong aggregation after freeze-drying. This negative performance of 
lactose was previously reported, being attributed to its poor protective effect during the 
freezing step (Hirsjärvi et al., 2009). Notwithstanding the apparent ability of glucose for 
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the physicochemical stabilisation of CRG/AP nanoparticles, this excipient should be 
used cautiously, as it has been referred as not adequate for protein formulations, because 
of its reducing character (Li et al., 1996; Wang, 2000). Nevertheless, the freeze-drying 
of protein nanocarriers in presence of glucose has been reported as efficient, not only 
regarding the physicochemical stability of the carrier, but also considering the 
maintenance of protein properties (Freixeiro et al., 2013). In any case, a comprehensive 
review on the subject suggests that it should be evaluated on a case-by-case basis 
(Wang, 2000).  
SP/CS nanoparticles demonstrated an easier stabilisation. Again, lactose demonstrated 
to be ineffective as cryoprotectant, although the obtained sizes were much lower as 
compared to those of CRG/AP nanoparticles when stabilised by the disaccharide. 
Sucrose, glucose and trehalose presented in this case a comparable behaviour, generally 
maintaining the stability of nanoparticles, even at the lower concentration of 2.5%. A 
concentration of 10% sucrose or glucose resulted in a mean size slightly lower than that 
observed before freeze-drying. This effect was observed in other studies, evidencing a 
compaction of nanoparticle structure during the freeze-drying process (de la Fuente et 
al., 2008b).  
It is noteworthy that both formulations of nanoparticles responded differently to the 
presence of the tested cryoprotectants. CRG/AP nanoparticles evidenced a Df/Di ratio 
between 1 and 3, which was many times close to or above 2, demanding higher 
cryoprotectant concentrations to achieve a stabilising effect. On the contrary, the Df/Di 
ratio observed for SP/CS nanoparticles varied between 1 and 2 and in most cases 
remained close to 1, indicating that lower cryoprotectant concentrations were sufficient 
for the stabilisation of nanoparticles. These differences are possibly related with the 
composition of nanoparticles. Different chemical groups are exposed to the outer 
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surface in each formulation and, consequently, the interaction mediated with the 
cryoprotectant is different (Abdelwahed et al., 2006), an effect that is known to greatly 
affect the cryoprotective effect. 
Although the obtained results suggest that the conditions to stabilise both formulations 
of nanoparticles were found, a relevant subsequent step is testing the stability of 
protein-loaded nanoparticles, as it is known that the entrapped drug may influence the 
freeze-drying of nanoparticles (Abdelwahed et al., 2006). Additionally, and particularly 
in the case of CRG/AP nanoparticles, the stabilisation conditions can be improved to 
avoid the slight size increase that is still observed when glucose is used as 
cryoprotectant. The studies should also be further completed to verify whether freeze-
drying affects the release pattern and the biological activity of the encapsulated protein. 
 
3.4. In vitro cytotoxicity study of pullulan-based nanoparticles 
Addressing the biocompatibility of drug carriers is a major issue in developing drug 
delivery systems (Gaspar and Duncan, 2009; Liu et al., 2008; Rodrigues et al., 2012a) 
and current international guidelines require the contextualisation of biocompatibility 
with a specific route of administration and dose of the material (Gaspar and Duncan, 
2009). In turn, it is also mandatory to treat polymers and polymer-based carriers as 
different entities, as the proper carrier structure, among other parameters, might affect 
the final behaviour (Aillon et al., 2009; Gaspar and Duncan, 2009; Williams, 2008). 
According to the guidelines issued by the International Organisation for Standardisation 
(ISO), testing biocompatibility implies the performance of a complete set of assays, 
addressing at first cellular morphology, membrane integrity and metabolic efficiency, 
but in some cases also including genotoxicity, as well as acute and sub-acute toxicity 
(ISO, 2003, 2009a, b; Rodrigues et al., 2012a). In this work we performed one of the 
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most used assays to test the cytotoxicity of materials and carriers, which is the 
metabolic assay MTT. This assay assesses cells metabolic efficiency, relying on the 
evaluation of enzymatic function. To do so, after the exposure to the test 
materials/carriers, cells are incubated with yellow tetrazolium (MTT) salts which are 
reduced to purple-blue formazan crystals by active mitochondrial dehydrogenases 
(Rodrigues et al., 2012a). In this manner, a higher concentration of the formazan dye 
corresponds to a higher amount of metabolically active cells, which is usually 
interpreted as higher cell viability. 
The Calu-3 is an immortalised cell line obtained from lung adenocarcinoma and has 
been extensively used in the study of formulations designed for either nasal or 
pulmonary drug administration, as it is considered a model of the epithelium of both 
regions (Casettari et al., 2010; Grainger et al., 2006; Zhu et al., 2010). Importantly, the 
MTT assay has been referenced as an effective tool to evaluate and compare the toxicity 
of materials on respiratory cells, namely the Calu-3 (Scherließ, 2011). 
The MTT assay was performed according to a factorial design consisting of either 
twelve (nanoparticles) or thirty (polymers) factor/level combinations. Figure 5 depicts 
the general statistic outcome, evidencing the variables and combinations that have an 
effect on cell viability (Y). Concerning the polymers (Figure 5A), the type of polymer 
(X3) and the used concentration (X2) were found to have the most relevant effect on cell 
viability, followed by the combinations time/type of polymer (X1*X3), 
concentration/type of polymer (X2*X3) and the three-way interaction (X1*X2*X3) (P < 
0.05). Obtaining a statistically significant effect indicates that the means of the groups 
are significantly different. However, it does not inform on which pairs of means the 
significant differences refer to. To do so, the analysis should include testing the various 
levels of the variables. Testing the levels of X1 (3h and 24h) with other variables 
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revealed statistical differences (P < 0.05) for some polymers (CS, CRG, AP).  
Nevertheless, as can be observed in Figure 6, the differences are generally devoid of 
biological relevance, as cell viability remains around 80-100%, which is considered 
very acceptable. Noticeably, at 3h (Figure 6A) aminated pullulan induces cell 
viabilities between 70% and 45%. For this pullulan derivative, there is a concentration 
dependent behaviour, as the cytotoxic effect is much more pronounced for 0.5 and 1.0 
mg/ml (50-45% cell viability) than for 0.1 mg/ml (69% cell viability) (P < 0.05). Upon 
24h exposure (Figure 6B), all polymers resulted in cell viability above 80%, with the 
exception of aminated pullulan. The latter registered the highest toxicity (P < 0.05), 
decreasing cell viability to 42-49%, independently of the concentration. Aminated 
pullulan is thus observed to have a clear time-dependent effect (P < 0.05), evidencing 
the most differentiating behaviour, corresponding to a cytotoxic effect. 
The influence of surface charges on cytotoxicity remains largely unresolved, but there 
are many indications suggesting a role of this parameter on cellular uptake and on the 
cytotoxicity of substances. In this context, positively charged materials have been 
frequently found to be more cytotoxic than neutral or negatively charged counterparts, 
because positive charges provide a means for stronger interaction with cell surfaces, in 
many cases associated with internalisation of the material (Bhattacharjee et al., 2010; 
Ilinskaya et al., 2002; Turcotte et al., 2009). Curiously, in this case, although chitosan is 
also positively charged, it does not evidence any cytotoxic effect, cell viability 
remaining around 100% irrespective of the used dose or time of exposure to the 
polymer solution. Two possible justifications for that effect could be a different charge 
density and a different size of the polymer chains. Regarding the latter parameter, an 
interesting work on the subject evaluated the cytotoxic effect of cationic pullulan 
microparticles on human leukemic K562(S) cells, demonstrating that increased molar 
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concentration of amino groups induced higher cytotoxicity (Constantin et al., 2003). 
Chitosan and aminated pullulan have approximately the same number of positive 
charges (0.8/chitosan monomer and 1/aminated pullulan monomer), thus not 
constituting a possible explanation for such a different behaviour. In parallel, the 
polymers present similar molecular weight. The main reason for the different behaviour 
should be instead the fact that amino groups of chitosan tend to deprotonate above the 
pKa of the polymer (approximately 6.4) while pullulan remains positively charged at pH 
7.4, which is approximately that of the nanoparticle suspension in cell culture medium.  
Although not directly used in the production of the nanoparticles presented in this work, 
unmodified pullulan was also tested, because its application in drug delivery has been 
reported, but data on its effect on epithelial cells are not available on the literature. As 
can be observed, its effect was found to not depend neither on concentration nor on 
time, resulting in approximately 75-85% cell viability in all cases. This is consistent 
with results reporting the application of pullulan coating to reduce the cytotoxicity of 
superparamagnetic iron oxide nanoparticles when in contact with human fibroblasts 
(hTERT-BJ1 cells) (Gupta and Gupta, 2005) or the same effect when coating magnetite 
nanoparticles (L929 fibroblasts) (Gao et al., 2010). As such, the coupling of cholesterol-
modified pullulan nanoparticles to amiloid-β oligomers was found to reduce the 
cytotoxicity associated with the oligomers (Boridy et al., 2009), which are thought to 
have a role on Alzheimer’s disease (Sakono and Zako, 2010).  
The most prominent result of the cytotoxicity study performed in this work is the fact 
that, notwithstanding the cytotoxic effect of some raw materials composing the 
nanocarriers, the exposure to the nanoparticle formulations for 3h or 24h results in cell 
viabilities between 74% and 94% (Figure 7). These values reveal that, independently of 
the formulation, concentration or time of incubation, the developed nanoparticles elicit 
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biologically acceptable cell viabilities. Nevertheless, the statistical analysis of results 
revealed that some variables had a stronger effect on cell viability as compared with 
others. As can be observed in Figure 5B, a significant effect on cell viability was found 
for concentration (X2), for the interaction between time of incubation and nanoparticle 
formulations (X1*X3), and also for the three-way interaction (X1*X2*X3) (P < 0.05). 
The effect plot suggests that the concentration has one of the most important effects on 
cell viability and, therefore, the three levels of concentration (0.1, 0.5 and 1.0 mg/ml) 
were compared. The results generally indicate that the lower concentrations (0.1 and 0.5 
mg/ml) have a similar contribution to cell viability, as a concentration increase at this 
level does not have a significant effect. In turn, when nanoparticle concentration is 
increased to 1 mg/ml, cell viability tends to decrease significantly (P < 0.05).  
Additionally, the analysis of simple effects was performed regarding the three-way 
interaction term. It was found that, for 3h incubation with CRG/AP nanoparticles, an 
increase in concentration from 0.5 to 1 mg/ml induced a decrease in cell viability from 
87% to 74% (P < 0.05). At 24h, cell viability remained constant around 88%. For SP/CS 
nanoparticles, an effect of concentration was only observed at 24h, as the viability 
decreased from 92% (0.1 mg/ml) to 78% when concentration increased to 1 mg/ml. It 
was found that both formulations presented a different response to the higher 
concentration of nanoparticles (1 mg/ml) both at 3h and 24h of incubation. Curiously, 
while SP/CS nanoparticles induced a viability decrease from 90% to 79% (P < 0.05) by 
prolonging the contact time, the opposite was observed for CRG/AP nanoparticles, as 
cell viability increased from 75% to 89% (P < 0.05). Although no plausible justification 
could be found for that event, it was considered that it does not compromise the general 
trend of results. 
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It is important to highlight that the above mentioned tendency of higher toxicity of 
positively charged materials has been reported many times regarding nanoparticles 
(Zobel et al., 1999). Nevertheless, this has not been the case for the nanoparticles 
produced and assessed in this work, although they exhibit a highly positive surface 
charge. 
To our knowledge, the assessment of the cytotoxic effect of pullulan-based 
nanoparticles on epithelial cells, either Calu-3 or other cell line, has never been 
reported, thus hindering a valuable and effective comparison. Nevertheless, although 
performed at different conditions, several works report the absence of a cytotoxic effect 
of pullulan nanoparticles on various types of cells, like human fibroblasts h-TERT BJ1 
(Gupta and Gupta, 2004a), monkey fibroblasts COS-7, human embryonic kidney cells 
HEK 293 (Gupta and Gupta, 2004b) and mouse macrophage-like cells RAW264.7 (Lee 
et al., 2012). 
As a general trend, it is thus considered that the contact of pullulan-based nanoparticles 
with the epithelial cells representative of nasal and lung mucosa, does not have an overt 
effect on cell metabolic activity, thus not compromising normal metabolic functions that 
are essential for surviving. 
 
4. Conclusions 
In this work, aminated and sulfated derivatives of pullulan demonstrated to have the 
ability to easily assemble into nanoparticles upon polyelectrolyte complexation with 
either carrageenan or chitosan. The produced nanoparticles displayed size around 200 
nm and the strongly positive zeta potential (approximately + 50 mV). Storing the 
nanoparticle suspensions at 4 ºC preserved their physicochemical characteristics (size 
and zeta potential) for up to one month, while freeze-drying in presence of a 
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cryoprotectant like glucose also provided stability. The capacity of the nanocarriers to 
associate a model protein (BSA) was satisfactory and there is great evidence of absence 
of overt toxicity of the pullulan-based nano delivery systems on a respiratory cell line 
(Calu-3). Based on these results, and taking into account the reported bioadhesiveness 
of pullulan, pullulan-based nanoparticles are believed to hold potential for an 
application in transmucosal protein delivery, with a particular focus on the nasal and 
pulmonary routes. 
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Figure captions 
Figure 1. A) Chemical structures of chitosan (CS), k-carrageenan (CRG) and pullulan 
derivatives, B) FTIR spectra of CS, sulfated pullulan (SP), SP/CS nanoparticles, bovine 
serum albumin (BSA)-loaded SP/CS nanoparticles and BSA; and C) CRG, aminated 
pullulan (AP), CRG/AP nanoparticles, BSA-loaded CRG/AP nanoparticles and BSA. 
 
Figure 2. TEM microphotographs of pullulan-based nanoparticles: A) nanoparticles 
SP/CS = 1/2 and B) nanoparticles CRG/AP = 1/2. 
 
Figure 3. In vitro release of BSA from () SP/CS nanoparticles and () CRG/AP 
nanoparticles assessed in PBS pH 7.4 at 37 ºC (mean ± S.D., n = 3). 
 
Figure 4. Size variation of A) CRG/AP = 1/2 and B) SP/CS = 1/2 nanoparticles, upon 
freeze-drying in presence of sucrose (black), lactose (dark grey), trehalose (light grey) 
and glucose (white), and further reconstitution in water (hydrodynamic diameter of 
nanoparticles before (Di) and after (Df) freeze-drying) (mean ± S.D., n = 3). 
 
Figure 5. Half normal plots of the effects obtained from the factorial design of the assay 
variables: time (X1), concentration (X2) and type of polymer/nanoparticles (X3), 
on Calu-3 cells viability. A) Polymers and B) Nanoparticles (* indicates the statistically 
significant effects). 
 
Figure 6. Calu-3 cell viability measured by MTT assay after A) 3h and B) 24h exposure 
to increasing concentrations of () chitosan, () carrageenan, (●) unmodified pullulan, 
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() sulfated pullulan and () aminated pullulan. Data represent mean ± S.E.M. (n = 3, 
six replicates per experiment at each concentration). 
 
Figure 7. Calu-3 cell viability measured by MTT assay after 3h (empty symbols) and 
24h (black symbols) exposure to increasing concentrations of () SP/CS nanoparticles 
and (○) CRG/AP nanoparticles. Data represent mean ± S.E.M. (n = 3, six replicates per 
experiment at each concentration). 
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Table 1. Physicochemical characteristics, production yield and bovine serum albumin 
encapsulation efficiency of pullulan-based nanoparticles (mean ± S.D., n = 3). 
Nanoparticle 
formulation 
Size (nm) ζ-potential 
(mV) 
Production 
yield (%) 
Encapsulation
efficiency (%) 
Loading capacity 
(%) 
SP/CS = 1/2 
Unloaded 
261 ± 42 + 50 ± 7 26 ± 9 __ __ 
SP/CS = 1/2 
BSA-loaded 
271 ± 50 + 50 ± 9 28 ± 8 44 ± 13 30 ± 8 
CRG/AP = 1/2 
Unloaded 
185 ± 44 + 56 ± 9 18 ± 8 __ __ 
CRG/AP = 1/2 
BSA-loaded 
244 ± 50 + 58 ± 8 19 ± 9 34 ± 7 31 ± 6 
AP: aminated pullulan; BSA: bovine serum albumin; CRG: carrageenan; CS: chitosan; SP: sulfated pullulan 
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